"Wenyi Kangle small molecule new drug R & D center" to build a research platform for anti influenza small molecule drugs

Qu Jia, President of Wenzhou Medical University, Li Xuekun, vice president, Xu Shundong, director of the Municipal Science and Technology Bureau, Li Zuohang, director of the talent office, Bai Zhiping, chairman of Kangle pharmaceutical, and Zhang Ao, researcher of Shanghai Institute of medicine, Chinese Academy of Sciences, unveiled the R & D center Liang Guang, vice president of the school of pharmacy, and Yu Yonghua, general manager of Kangle pharmaceutical signed the contract on behalf of both parties Li Xuekun presided over the Establishment Ceremony Qu Jia, Bai Zhiping, Xu Shundong and Li Zuohang delivered speeches at the ceremony successively "The new drug research and development center we set up will mainly carry out the research and development of the neuraminidase inhibitors of influenza virus, that is to say, the drugs we want to develop are for the treatment of various influenza diseases." Liang Guang, a professor at the school of pharmacy of Wenzhou Medical University and head of the research and development center, said "Colleges and universities serve the development of local enterprises through technology and talents Enterprises carry the transformation of efficient technological achievements and help the development of teaching and scientific research in Colleges and universities, while high-level talents repay the society through scientific research achievements." Bai Zhiping, chairman of Kangle company, believes that the combination of production, learning and research can better reflect that science and technology is the first productivity "Our new drug has begun to be developed in the early stage After successful development, the drug will have better effects and less side effects than Tamiflu." Liang Guang said confidently From SARS in 2003, avian influenza in 2004, H1N1 in 2009, to the Ebola virus with high infection rate and high mortality, even in the modern society with advanced technology, human beings still face the threat of all kinds of dangerous epidemic virus diseases The Wenyi Kangle small molecule new drug R & D center, which is composed of universities, enterprises and high-level talents, mainly carries out the research and development of influenza virus neuraminidase inhibitors, realizes the innovation of cooperation mechanism and complementary advantages and resources by building a cooperation platform of production, education and research, so as to help the transformation of scientific and technological achievements and high-end projects of "national thousand talents" and other high-level talents in Wenzhou to serve Promotion of local social economy and enterprise development In order to give full play to their respective advantages, the three parties have formulated a clear division of labor for the development of small molecule new drugs: Professor Gu Yugui is mainly responsible for the design and technical guidance of new drugs, the school of pharmacy of our university is responsible for the pre clinical research of small molecule drugs, such as the early synthesis, screening, pharmacological and pharmaceutical generation, and the leisure pharmaceutical industry is responsible for the later pilot scale-up, quality control, registration and application The three parties jointly invested in the construction of R & D center and project R & D, hoping that through 3-5 years, the R & D center will find and complete a preclinical study of a new anti influenza molecular entity drug with independent intellectual property rights At the unveiling ceremony, Dr Jiang Lei, vice general manager and President of scientific research of Shanghai Haihe pharmaceutical research and Development Co., Ltd., researcher Zhang Ao of Shanghai Institute of Pharmaceutical Sciences, Professor Sun Hongbin, director of new drug research center of China University of Pharmaceutical Sciences, was hired as visiting professor and senior consultant of Wenyi Kangle small molecule new drug research and development center of our school of pharmacy, and then made a speech for the teachers and students attending the ceremony Academic report on the progress of small molecule new drug research and development At the same time, Kangle pharmaceutical announced to donate 100000 yuan to our school to establish a Kangle pharmaceutical scholarship Over the years, the school of pharmacy of Wenzhou Medical University has formulated the development strategy of both basic research and industrial application around the direction of new drug research and development The college now undertakes the construction task of the first level discipline in the top priority of pharmacy in Zhejiang Province It has obtained more than 100 major scientific research projects, including national "973" and "863" projects, national major new drug creation projects, National Natural Science Foundation major research projects and international cooperation projects, with a total fund of over 100 million yuan, more than 60 invention patents authorized, and more than 300 high-level academic papers published It has won many national science and technology awards, such as the National Technology Invention Award, the national science and technology progress award, and the Chinese Medical Association Award Zhejiang Kangle Pharmaceutical Co., Ltd is the largest and oldest pharmaceutical enterprise in Wenzhou It mainly produces APIs such as chemical APIs, antibiotics, botanical drugs, and more than 100 varieties of preparations such as large volume injections, oral solid preparations, small volume injections, powder injections and pharmaceutical intermediates The company's main products are sold to the United States, the European Union, Japan, South Korea, Russia and other countries, especially the company's flagship product, paracetamol, which ranks first in the world in terms of global market share and has certain popularity and influence in the international pharmaceutical industry Gu Yugui, a senior expert in the field of chemical drug research and development, has more than 20 years of rich experience in new drug research and team management He has successively worked in Abbott and carbiste, two internationally renowned pharmaceutical companies, mainly engaged in the development of new drugs in the fields of anti influenza, antibacterial, anti-tumor, diabetes drugs, etc many new compound entity drugs, such as cb-618, abt-210, abt-431 and abt-677, which he has presided over and developed, have entered different stages of clinical research or have been successfully listed in the United States